A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

What this study is about

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

Who can join (things the study team will check)

✅ You may be able to join if…

• Completion of the 52-week treatment period in either parent GB43311 or GB44332

🚫 You may not be able to join if…

• Withdrawal of consent and/or premature discontinuation from parent study
• Any permanent discontinuation of study drug in parent study
• Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment
• Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study
• Any new clinically significant pulmonary disease other than COPD (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study
• Any new unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure since enrolling in the parent study

Where this trial is running

• UAB Lung Health Center, Birmingham, Alabama, United States
• SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS, Dothan, Alabama, United States
• Jasper Summit Research LLC, Jasper, Alabama, United States
• Pulmonary Associates of Mobile PC, Mobile, Alabama, United States
• Pulmonary Associates Deer Valley Office, Phoenix, Arizona, United States
• AES - DRS - Synexus Clinical Research US, Inc. - Tucson, Tucson, Arizona, United States
• Kern Allergy and Medical Research, Bakersfield, California, United States
• Cadena Care Institute, LLC, Poway, California, United States
• Apex Clinical Research, San Diego, California, United States
• St Francis Medical Institute ClinEdge PPDS, Clearwater, Florida, United States
• Finlay Medical Research Corporation, Greenacres City, Florida, United States
• Flourish Research - Leesburg - PPDS, Leesburg, Florida, United States

+ 474 more sites.

Who to contact

Reference Study ID Number: GB43374 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 · global-roche-genentech-trials@gene.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05878769.